Vertex Triple Combo, Kaftrio, Approved for CF Patients in EU With F508del Mutation
The European Commission (EC) approved Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor) to treat cystic fibrosis (CF) in people 12 and older who have either two F508del mutations or one F508del mutation and one minimal function mutation in the CFTR gene. The decision follows a positive opinion,…